“…For example, RAS mutations have been shown to underlie the development of SCCs and other squamoproliferative lesions occurring in melanoma patients treated with BRAF inhibitor targeted monotherapies. 2,3 There are now 22 cases (including our own) reported of eruptive KAs occurring in patients treated with anti-PD1 immunotherapies in the context of treatment for metastatic SCC, [4][5][6][7] metastatic lung adenocarcinoma, 8 renal cell carcinoma, 9,10 pancreatic cancer, 6 apocrine carcinoma, 11 metastatic ureteral carcinoma, 12 melanoma, 7,8,[13][14][15] and mesothelioma. 8 These have arisen in the setting of other anti-PD1-associated skin eruptions, including lichenoid eruptions, 6,8,9,12 bullous pemphigoid-like eruptions 14 and a psoriasis flair.…”